Platelet‐associated IgG and IgM in myelofibrosis

HANS HASSELBALCH*, DAG BERILD, OLE PAASKE HANSEN

*Corresponding author af dette arbejde

    Publikation: Bidrag til tidsskriftArtikelForskningpeer review

    Abstrakt

    Elevated levels of platelet‐associated IgG and/or IgM were found in 15 of 18 patients with myelofibrosis (83 %). All but 5 patients with elevated PAIg had active disease. The amounts of PAIg were not correlated to either S‐Ig, platelet count or spleen size. Levels of PAIgG well above the normal range were especially found in patients with short duration of disease and/or a transitional myeloproliferative state. It is debated whether immune‐mediated platelet dysfunction may be of importance for the development of bone marrow fibrosis, mediated by the release of platelet‐derived growth factors in the bone marrow. Elevated PAIg may also contribute to abnormal haemostasis and thrombocytopenia in myelofibrosis.

    OriginalsprogEngelsk
    Sider (fra-til)488-492
    Antal sider5
    TidsskriftScandinavian Journal of Haematology
    Vol/bind32
    Udgave nummer5
    DOI
    StatusUdgivet - maj 1984

    Fingeraftryk

    Udforsk hvilke forskningsemner 'Platelet‐associated IgG and IgM in myelofibrosis' indeholder.

    Citationsformater